Neopharm: Median survival time hits 44 weeks in cintredekin besudotox trial

By Angela McDaniels

Seattle, Sept. 18 - Neopharm, Inc. said that in long-term follow up data from its phase 1/ 2 clinical studies, cintredekin besudotox (IL13-PE38QQR) continues to show evidence of prolonged overall survival in patients with recurrent glioblastoma multiforme.

The overall median survival for patients who received cintredekin besudotox is 44 weeks, according to a company news release, and median survival increased to 55.6 weeks for the 27 patients with two or more optimally placed catheters.

The data was presented on Saturday at the European Association of Neuro Oncology meeting in Vienna by Sandeep Kunwar of the University of California, San Francisco, the principal investigator of the company's ongoing phase 3 Precise trial for cintredekin besudotox.

Additionally, an independent statistical analysis of the phase 1/ 2 data confirmed that catheter placement was a key prognostic factor related to prolonged survival, the Waukegan, Ill.-based cancer drug development company said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.